Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FYI - DarioHealth's Digital Therapeutics Solution Selected as Employee Health Benefit by Self-Insured, Fortune 500 Subsidiary
https://finance.yahoo.com/news/dariohealths-digital-therapeutics-solution-selected-130000797.html
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreement to provide its digital therapeutics solution to eligible employees of a subsidiary of a U.S. based Fortune 500 technology and engineering company.
"Helping employees manage chronic health issues such as diabetes and hypertension are critical to employers," said Kellien Bailey, Senior Director, Strategic Partnerships at Vitality Group. "To support these needs, we partnered with DarioHealth to incorporate their chronic conditions management programs into our Gateway Flex offering. We look forward to working with DarioHealth to help our clients achieve better, healthier outcomes."
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device.
FYI - Senseonics' 180-day Eversense glucose monitor delayed at FDA by COVID-19 pandemic
https://www.fiercebiotech.com/medtech/senseonics-180-day-eversense-glucose-monitor-delayed-at-fda-by-covid-19-pandemic
Senseonics’ plans to roll out its new, long-term diabetes sensor implant will be pushed to the middle of next year as FDA reviewers continue to be swamped by product submissions aimed at the COVID-19 pandemic.
The upcoming version of the Senseonics Eversense continuous glucose monitoring system—a smartphone-connected device, first approved in June 2018, that's inserted completely under the skin—aims to double its life span from 90 days to six months.
But the company has received word from the FDA to expect delays of at least two months for its application while the agency tasks its staff with emergency reviews of coronavirus tests and other medical devices, it said.
The setback matches what Senseonics has heard from other medtech developers currently trying to get their products reviewed, the company said, noting that there's still potential for the FDA to reach an approval decision before the end of 2021’s second quarter.
Earlier this year, the head of the FDA’s device center, Jeff Shuren, described a tsunami of product applications from companies hoping to join the fight against the COVID-19 pandemic—including over 1,200 submissions for diagnostic tests, ventilators, digital tech and more by early October—which has begun to slow the agency’s work in other diseases.
Describing it as a “canary in the coal mine,” Shuren said review times had begun to increase amid growing backlogs due to the high volume. In addition, the FDA may not be able to make commitments to meeting company timelines going forward, officials said at the time
FYI - Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor
https://finance.yahoo.com/news/nemaura-medical-launches-beat-diabetes-130000308.html
Early infrared prototype on the ear lobe.
https://www.knowlabs.co/about
If you click the above link and scroll to the bottom of the page you will see a pic of Phil wearing a prototype on his ear lobe.
DXCM CEO Kevin Sayer Talks Dexcom's Growth in 2020
FYI - Smart tech earring is CGM game-changer
The Sense Glucose Earring uses smart CGM to transform the way patients manage type 1 diabetes.
https://www.longevity.technology/smart-tech-earring-is-cgm-game-changer/
FYI - When Diabetes Devices Fail
https://www.yahoo.com/news/diabetes-devices-fail-110007775.html
FYI - Tech Updates: G7 CGM, DIY LoopLink, Glucose Prediction Apps
https://diatribe.org/tech-updates-g7-cgm-diy-looplink-glucose-prediction-apps
DiabetesMine Innovation Days 2020 featured exciting advances in diabetes technology. While many upcoming diabetes devices are currently experiencing delays in clearance and marketing due to COVID-19, we bring you some highlights from the virtual conference – including devices to look forward to and apps that are already available.
FYI PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results
https://seekingalpha.com/article/4389889-pavmeds-pavm-ceo-lishan-aklog-on-q3-2020-results-earnings-call-transcript
our Solys non-invasive NDIR laser-based blood glucose monitoring technology is also progressing well. We recently completed initial animal testing of a first-generation prototype and a diabetic rat model. Those results were sufficiently accurate to allow us to achieve the R&D plan milestone as defined in our license agreement. We developed a second generation prototype with dramatically improved signal-to-noise ratio, which should be ready for human volunteers testing in that front.
Better Buy: Abbott Laboratories vs. DexCom
These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon.
https://www.fool.com/investing/2020/11/17/better-buy-abbott-laboratories-vs-dexcom/
FYI - DexCom: The End Of The Beginning Is Almost Here
https://seekingalpha.com/article/4389080-dexcom-end-of-beginning-is-almost
Thanks for thoughts; FYI, Without FDA approval, P. Bosua, will be leaving A LOT on the table; as he is scheduled to receive 1.2 million shares of Know common stock on UBAND FDA approval.
Form 10-Q June 30, 2020
On November 4, 2019, the Company granted a stock option grant to Philip A. Bosua for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon FDA approval of the UBAND blood glucose monitor.
With past interviews done by BioPub with Know Labs, both Dr. KSS and Phil Bosua make several references to Dexcom and its market cap. So as to size Know labs to Dexcom potential market capitalization growth; which is currently at a market cap of 34 billion. Why would Know Labs be successful at the Mayo Clinic; only to spin off the UBand technology and not reap the profit potential?
Apr 10, 2020
FYI - How Apple Plans To Become A Big Player In Health Care
FYI - PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Aug. 18, 2020
https://seekingalpha.com/article/4369601-pavmed-inc-pavm-ceo-lishan-aklog-on-q2-2020-results-and-business-update-earnings-call?part=single
The research and development plan for our non-invasive laser based blood glucose modern technology, licensed by our subsidiary Solys Diagnostics has made excellent progress during this period. We successfully completed preliminary human testing, demonstrating testing accuracy within established FDA and ISO standards to normal human volunteers with moderately elevated blood glucose after high sugar [meal]. We hope to advance Solys development to achieve FDA and ISO accuracy standards for the full range of blood glucose required by the standards in the coming months.
FYI - Why Insulin Pumps Are Finally Getting Smarter
FYI - Apple still has a lot of room to grow in the $3.5 trillion health care sector.
https://www.cnbc.com/2020/06/20/apple-still-has-a-lot-of-room-to-grow-in-health-care.html?&qsearchterm=apple%20still%20has
Another game-changer would be if Apple can introduce more sophisticated sensors, including non-invasive glucose or blood sugar monitoring or a blood-pressure monitor. At that point, its device could reach a much bigger market -- 6 in 10 Americans - with one or more chronic diseases, as well as prevention. More than 1 in 3 Americans, for instance, are at high risk for type 2 diabetes.
“If they came out with a blood sugar or blood pressure monitor that was non-invasive and continuous, it would be a complete game changer,” said Berggren. “That’s what we dream about for the watch.”
FYI - Medtronic announces $337 mln product investment from Blackstone for diabetes research (93.20 +2.30)
Medtronic and Blackstone (BX) announce that Medtronic intends to significantly increase R&D funding in its Diabetes Group through an agreement to receive $337 mln of funding from funds managed by Blackstone Life Sciences including co-investors, aimed at advancing new, innovative products especially designed to reduce the burden of diabetes management.
The announcement was made in conjunction with the start of the virtual 80th Scientific Sessions of the American Diabetes Association (ADA).
FYI - PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update
As I mentioned, Solys Diagnostics research and development plan for our noninvasive NDIR laser-based blood glucose monitoring technology is progressing very well. The working prototype has been completed and has been tested in a bench-top model. These fairly recent results show a very nice linear response curve across a wide range of glucose concentrations.
We expect to be -- to complete human and animal testing in the coming weeks. If that goes well and we achieve our target accuracy threshold we will be able to proceed on a commercial development plan.
Things can’t be all bad at Know Labs as Phil and Ron both got pay raises.
On April 29, 2020, the Company increased the salary of Ronald P. Erickson and Phillip A. Bosua by $20,000 per year.
Professor Furness
Tom is a professor at the University of Washington (UW) in the Department of Industrial & Systems Engineering, with adjunct appointments in Electrical Engineering, Mechanical Engineering and Human Centered Design and Engineering. He founded the Human Interface Technologies Lab (HITLab) at the university and its sister locations in New Zealand and Australia. He is also the founder and General Manager at the RATLab and Virtual World Society.
Often referred to as “The Grandfather of Virtual Reality,” Professor Furness has done notable work in the field of VR. As a pioneer in this field, he is most well known for his contributions in developing technologies that interface humans to advanced machines, which much of his early work centered on virtual interface technologies. Over the past 26 years, Tom and his students have started 27 companies (two of which are traded on NASDAQ with a market capitalization of >$8B).
In June 2015, Professor Furness received the first-ever lifetime achievement award for his 50-years service in the field of VR and AR from Augmented World Expo (AWE) in Santa Clara, California. He has also received the SPIE Prism Award for his invention of the ChromaID technology and the Discover Award for his invention of the Virtual Retinal Display.
http://www.ratlab.us/site/founder/
https://en.wikipedia.org/wiki/Thomas_A._Furness_III
In after hours trading today, DexCom, Inc. stock price closed at $384.09 and the stock was added to the S&P 500 and Baron Asset Fund is a big holder of DexCom.
Here’s Why Baron Asset Fund Likes DexCom (DXCM) Stock
https://finance.yahoo.com/news/why-baron-asset-fund-likes-164131534.html
With that said, if and when Know Labs, Inc. is able to bring their Non-invasive UBAND Continuous Glucose Monitor (CGM) to market; what is anybody's guess at what the share price of Know Labs will be?
FYI - With its latest acquisition, One Drop looks to integrate Sano Intelligence's CGM wearable for broader health monitoring.
https://www.mobihealthnews.com/news/its-latest-acquisition-one-drop-looks-integrate-sano-intelligences-cgm-wearable-broader-health
BioPub.co Presents: Know Labs (KNWN) April 10th 2020
It's my understanding that Dr. Mark Tapasak is serving Know Labs, in an advisory role.
You don't think, that individuals at Know Labs, would go to the trouble of updating their website and posting YouTube videos (as of February 26, 2020) if the UBand CGM is a failure?
FYI - Nemaura Medical Launches Non-Invasive Glucose Monitor in the US
https://finance.yahoo.com/news/nemaura-medical-launches-non-invasive-161600375.html
From NEMAURA MEDICAL INC. 10K Filing March 31,2019
http://irdirect.net/filings/viewer/index/1602078/000107997319000357/
We are a medical technology company developing sugarBEAT®, a non-invasive, affordable and flexible continuous glucose monitoring system for adjunctive use by persons with diabetes. SugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals via a mobile app. SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The transmitter sends the raw data to a mobile app where it is processed by an algorithm and displayed as a glucose reading, with the ability to track and trend the data over days, weeks and months. While sugarBEAT requires once per day calibration by the patient using a blood sample obtained by a finger stick, we believe sugarBEAT will be adopted by non-insulin dependent persons with diabetes alongside insulin-injecting persons with diabetes who all perform multiple daily finger sticks to manage their disease.
New Video from Know Labs. 1-29-2020.
Know Labs. updated their website.
Maybe this could be things to come!
https://www.knowlabs.co/
New Know Lab. YouTube video up loaded 1-27-2020.
Dexcom CEO Kevin Sayer spoke with CNBC's Jim Cramer
FYI
DIY diabetes tech gains popularity with patients and parents fed up with clunky mainstream medical devices
https://www.washingtonpost.com/health/fed-up-with-clunky-diabetes-machines-do-it-yourselfers-re-engineer-devices-and-create-apps-and-software/2019/12/13/3f7c4e20-16c4-11ea-9110-3b34ce1d92b1_story.html
Know Labs Unveils New UBAND Design and Smartphone App
Know Labs Unveils New UBAND Design and Smartphone App
FYI
Know Labs will be presenting at the Diabetes Technology Society meeting on November 15, 2019 at the Start Up Showcase.
https://www.diabetestechnology.org/index.shtml#